<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860858</url>
  </required_header>
  <id_info>
    <org_study_id>18265_CREC032/59BPs</org_study_id>
    <nct_id>NCT02860858</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)</brief_title>
  <official_title>Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in
      patients with symptomatic macular PCV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Symtomatic Macular Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreous aflibercept injection</intervention_name>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female &gt;/= 18 years

          -  Confirmed diagnosis of symptomatic macular PCV in the study eye defined by: - Active
             macular polypoidal lesions shown by ICGA and - Presence of serosanguinous maculopathy

          -  BCVA letter score between 78-24 using ETDRS visual acuity chart measured at 4 meters

        Exclusion Criteria:

          -  Previous treatment with systemic anti-VEGF drugs within 6 months prior to Baseline
             (e.g., sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®])

        Study eye:

          -  Active ocular inflammation or infection (ocular or periocular)

          -  Uncontrolled intraocular hypertension or glaucoma (IOP&gt; 30 mmPIg) despite treatment
             with anti-glaucoma medication

          -  Predominantly-scarred PCV lesions

          -  Ocular disorders in the study eye (e.g. cataract, retinal vascular occlusion, diabetic
             retinopathy) that, in the opinion of the investigator may confound interpretation of
             study results or compromise VA or require medical or surgical intervention during the
             study period

          -  Prior treatment with verteporfin PDT, external-beam radiation, subfoveal or
             extrafoveal focal laser photocoagulation, submacular surgery, or transpupillary
             thermotherapy

          -  Prior treatment with any anti-VEGF compound or any investigational treatment

          -  Treatment with intravitreal or subtenon corticosteroid injection or device
             implantation within 90 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paisan Ruamviboonsuk, MD</last_name>
    <phone>6622062957</phone>
    <email>paisan.trs@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kanya Janpol</last_name>
    <phone>6623548108</phone>
    <email>kanyanana@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paisan Ruamviboonsuk, MD</last_name>
      <phone>6622062957</phone>
      <email>paisan.trs@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kanya Janpol</last_name>
      <phone>6623548108</phone>
      <email>kanyanana@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

